Related Experiment Videos
Monocyclic L-nucleosides with type 1 cytokine-inducing activity
K S Ramasamy1, R C Tam, J Bard
1Department of Chemistry, ICN Corporate Research, ICN Pharmaceuticals, Inc., 3300 Hyland Avenue, Costa Mesa, California 92626, USA. kramasamy@icnpharm.com
Journal of Medicinal Chemistry
|March 15, 2000
Summary
Researchers synthesized novel 1,2,4-triazole L-nucleosides to stimulate type 1 cytokine production. Compound ICN 17261 demonstrated potent immunomodulatory effects, showing promise for treating type 1 cytokine-related diseases.
Area of Science:
- Immunology
- Medicinal Chemistry
Background:
- Type 1 cytokines are crucial for immune responses.
- 1,2,4-triazole nucleosides are investigated for immunomodulatory properties.
Purpose of the Study:
- To synthesize and evaluate 1,2,4-triazole L-nucleosides for their capacity to stimulate type 1 cytokine production in human T cells.
- To compare the potency of synthesized compounds with ribavirin.
Main Methods:
- Synthesis of a series of 1,2,4-triazole L-nucleosides.
- Evaluation of cytokine production by activated human T cells.
- Comparative analysis with ribavirin.
Main Results:
- 1-beta-L-ribofuranosyl-1,2,4-triazole-3-carboxamide (ICN 17261) was identified as the most potent compound.
- A carboxamidine derivative (compound 10) showed comparable activity to ICN 17261 for two of three type 1 cytokines.
- Modifications to the carbohydrate moiety generally reduced activity.
Conclusions:
- ICN 17261 exhibits significant immunomodulatory potential.
- This compound may be a valuable therapeutic agent for diseases involving type 1 cytokines.